1. Home
  2. SLDP vs LBRX Comparison

SLDP vs LBRX Comparison

Compare SLDP & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Solid Power Inc.

SLDP

Solid Power Inc.

HOLD

Current Price

$3.12

Market Cap

662.3M

Sector

Energy

ML Signal

HOLD

LBRX

LB Pharmaceuticals Inc

N/A

Current Price

$26.33

Market Cap

602.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SLDP
LBRX
Founded
2011
2015
Country
United States
United States
Employees
230
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
662.3M
602.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SLDP
LBRX
Price
$3.12
$26.33
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$7.00
$47.00
AVG Volume (30 Days)
3.2M
246.4K
Earning Date
05-05-2026
05-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$48.90
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.04
$13.40
52 Week High
$8.86
$27.55

Technical Indicators

Market Signals
Indicator
SLDP
LBRX
Relative Strength Index (RSI) 49.14 57.59
Support Level $2.94 $22.39
Resistance Level $3.22 $27.45
Average True Range (ATR) 0.15 1.70
MACD 0.05 0.09
Stochastic Oscillator 78.07 81.78

Price Performance

Historical Comparison
SLDP
LBRX

About SLDP Solid Power Inc.

Solid Power Inc develops solid-state battery technology and manufacturing processes. Its sulfide-based solid electrolyte material replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells and enables improvement in energy density, battery life and safety performance. The company produces electrolytes on two pilot manufacturing lines using a batch manufacturing process for customer sampling and internal cell development, and manufactures solid-state cells on pre-pilot and pilot cell manufacturing lines. Its cell manufacturing processes are developed around industry-standard lithium-ion battery manufacturing processes and equipment, and it manufactures all cell designs, including cathodes and anodes, using materials sourced from external suppliers.

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.

Share on Social Networks: